Photodynamic Inhibition of Herpes Simplex Virus 1 Infection by Tricationic Amphiphilic Porphyrin with a Long Alkyl
Igor Jurak1, Maja Cokarić Brdovčak1, Lara Djaković1
1Department of Biotechnology, University of Rijeka, Radmile Matejčić 2, HR-51000 Rijeka, Croatia.
Abstract:
Photodynamic therapy (PDT) is broadly used to treat different tumors, and it is a rapidly developing approach to inactivating or inhibiting the replication of fungi, bacteria, and viruses. Herpes simplex virus 1 (HSV-1) is an important human pathogen and a frequently used model to study the effects of PDT on enveloped viruses. Although many photosensitizers (PSs) have been tested for their antiviral properties, analyses are usually limited to assessing the reduction in viral yield, and thus the molecular mechanisms of photodynamic inactivation (PDI) remain poorly understood. In this study, we investigated the antiviral properties of TMPyP3-C17H35, a tricationic amphiphilic porphyrin-based PS with a long alkyl chain. We show that light-activated TMPyP3-C17H35 can efficiently block virus replication at certain nM concentrations without exerting obvious cytotoxicity. Moreover, we show that the levels of viral proteins (immediate-early, early, and late genes) were greatly reduced in cells treated with subtoxic concentrations of TMPyP3-C17H35, resulting in markedly decreased viral replication. Interestingly, we observed a strong inhibitory effect of TMPyP3-C17H35 on the virus yield only when cells were treated before or shortly after infection. In addition to the antiviral activity of the internalized compound, we show that the compound dramatically reduces the infectivity of free virus in the supernatant. Overall, our results demonstrate that activated TMPyP3-C17H35 effectively inhibits HSV-1 replication and that it can be further developed as a potential novel treatment and used as a model to study photodynamic antimicrobial chemotherapy.
Insights
A novel photosensitizer, TMPyP3-C17H35, effectively inhibits herpes simplex virus 1 (HSV-1) replication and reduces viral infectivity. This photodynamic therapy approach shows promise for treating viral infections with minimal cytotoxicity.
Area of Science:
- Photodynamic therapy
- Antiviral research
- Virology
Background:
- Photodynamic therapy (PDT) is a versatile treatment for tumors and microbial infections.
- Herpes simplex virus 1 (HSV-1) serves as a model for studying PDT effects on enveloped viruses.
- Current understanding of PDT's molecular mechanisms against viruses is limited.
Purpose of the Study:
- To investigate the antiviral properties of TMPyP3-C17H35, a novel porphyrin-based photosensitizer.
- To assess the efficacy and mechanism of TMPyP3-C17H35 in inhibiting HSV-1 replication.
- To evaluate the potential of TMPyP3-C17H35 as a photodynamic antimicrobial chemotherapy agent.
Main Methods:
- Treatment of HSV-1 infected cells with light-activated TMPyP3-C17H35.
- Quantification of viral protein levels (immediate-early, early, and late genes).
- Assessment of viral yield and infectivity in cell culture supernatant.
Main Results:
- Light-activated TMPyP3-C17H35 efficiently blocked HSV-1 replication at nanomolar concentrations with low cytotoxicity.
- Significant reduction in viral protein expression and viral yield was observed.
- TMPyP3-C17H35 demonstrated efficacy when applied before or shortly after infection, and also reduced free virus infectivity.
Conclusions:
- Activated TMPyP3-C17H35 is a potent inhibitor of HSV-1 replication.
- The compound effectively reduces viral infectivity both intracellularly and extracellularly.
- TMPyP3-C17H35 holds potential as a novel antiviral therapeutic and a model for photodynamic antimicrobial chemotherapy research.
More Related Videos
Related Concept Videos
Herpes
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors


